Ketilept

Quetiapine fumarate, the active ingredient in Ketilept, is an atypical antipsychotic presented as an oral tablet for oral use. It is prescribed for the management of schizophrenia, bipolar disorder and as adjunct therapy in major depressive disorder in adult patients.

GNH USA supplies Ketilept as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Products are manufactured in EU‑certified facilities and undergo routine batch testing to ensure consistency.

Ketilept (quetiapine fumarate) acts on multiple neurotransmitter pathways and is indicated for several psychiatric conditions. - Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Bipolar disorder (manic episodes): stabilizes mood and decreases manic intensity. - Major depressive disorder (adjunct therapy): enhances antidepressant response when added to standard treatment.

Quetiapine fumarate may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness: feeling of sleepiness or reduced alertness. - Dry mouth: decreased salivation causing oral discomfort. - Weight gain: increase in body weight over time. - Constipation: reduced bowel movements leading to discomfort.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever, rigidity and autonomic instability. - Tardive dyskinesia: persistent involuntary movements, especially of the face and tongue. - Severe orthostatic hypotension: marked drop in blood pressure upon standing causing dizziness or fainting.

When prescribing quetiapine fumarate, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiovascular status: evaluate blood pressure and heart rate before initiating therapy. - Monitor metabolic parameters: regularly check weight, glucose and lipid levels during treatment. - Caution in elderly patients: increased sensitivity to sedation and falls risk. - Avoid abrupt discontinuation: taper the dose gradually to reduce withdrawal symptoms. - Pregnancy and lactation: weigh potential benefits against risks; consult obstetric guidance. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Quetiapine fumarate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase quetiapine plasma levels, raising risk of toxicity. - CNS depressants (e.g., alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower quetiapine concentrations, reducing therapeutic effect. - Antihypertensive agents: quetiapine may enhance orthostatic hypotension, requiring blood pressure monitoring.